Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis

<h3>Background</h3><p dir="ltr"><u>Chronic obstructive pulmonary disease </u>(COPD) significantly impacts global health due to persistent airflow limitation and inflammation. Despite standard therapies, symptoms persist. Ensifentrine, targeting both <u>bronchoconstriction</u> and inflammation as a dual phosphodiesterase 3 and 4 inhibitor, offers a promising therapeutic advancement for COPD management. This meta-analysis evaluates the safety and efficacy of ensifentrine in improving lung function, dyspnea, and quality of life in COPD patients. </p><h3>Methods</h3><p dir="ltr">We searched PubMed, Embase, and Web of Science through August 2024 for <u>randomized controlled trials</u> evaluating ensifentrine in COPD patients over a minimum of four weeks. Data extraction and screening utilized Knowledge software, and meta-analyses were performed using R v4.4 with a random-effects model. </p><h3>Results</h3><p dir="ltr">From 206 studies identified, four met our inclusion criteria. Ensifentrine improved FEV1 significantly at a dose of 3 mg (LS mean difference: 40.90 mL; 95 % CI: 19.65–62.15). It also improved dyspnea as measured by the Transition Dyspnea Index (TDI) (LS mean difference: 0.91; 95 % CI: 0.61–1.21) and quality of life according to the St. George's Respiratory Questionnaire-C (SGRQ-C) scores (LS mean difference: −1.92; 95 % CI: −3.28 to −0.55). Safety profiles were comparable between the ensifentrine and placebo groups, with no significant increase in treatment-emergent <u>adverse events</u> (TEAEs) (RR: 1.02; 95 % CI: 0.94–1.10). </p><h3>Conclusion</h3><p dir="ltr">Ensifentrine significantly enhances lung function, reduces dyspnea, and improves quality of life in COPD patients, especially at a 3mg dose. These benefits, coupled with a stable safety profile, support its use as an adjunctive therapy in COPD management.</p><h2>Other Information</h2><p dir="ltr">Published in: Respiratory Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.rmed.2024.107863" target="_blank">https://dx.doi.org/10.1016/j.rmed.2024.107863</a></p>